Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495774 | 0.98 | TSHR (0.37) | TSHRKDM4EALDH1A1TDP1 | |
| SCHEMBL1809020 | 0.96 | TSHR (0.38) | TSHRKDM4EALDH1A1TDP1RGS12 | |
| SCHEMBL7534039 | 0.76 | BRD4 (0.33) | TSHRTDP1 | |
| SCHEMBL19011596 | 0.73 | — | — | |
| SCHEMBL181531 | 0.67 | TSHR (0.35) | TSHRALDH1A1TDP1RGS12 | |
| SCHEMBL19858947 | 0.66 | TDP1 (0.32) | TSHRTDP1 | |
| SCHEMBL11363682 | 0.65 | TSHR (0.34) | TSHRTDP1 | |
| SCHEMBL9838534 | 0.64 | MEN1 (0.35) | TSHRTDP1RGS12 | |
| SCHEMBL11377208 | 0.63 | TSHR (0.32) | TSHR | |
| SCHEMBL11422629 | 0.60 | ALDH1A1 (0.47) | TSHRKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397137-A4 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1397137-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002096426-A1 | HYDANTION DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-12-05 | — | — | WO | disclosed |
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | AFFYMAX, INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2002011732-A1 | NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065309-A1 | Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists | GNRHR, FSHR, LHCGR | TSHR 134/4885KDM4E 1021/4885ALDH1A1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.